|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
|
CA1341245C
(en)
|
1988-01-12 |
2001-06-05 |
F. Hoffmann-La Roche Ag |
Recombinant vaccinia virus mva
|
|
US5298416A
(en)
|
1989-01-18 |
1994-03-29 |
British Technology Group Ltd. |
Attenuated polioviruses
|
|
US5505947A
(en)
|
1994-05-27 |
1996-04-09 |
The University Of North Carolina At Chapel Hill |
Attenuating mutations in Venezuelan Equine Encephalitis virus
|
|
UA68327C2
(en)
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
GB0023203D0
(en)
|
2000-09-21 |
2000-11-01 |
Isis Innovation |
Vaccination method
|
|
WO2003104467A1
(en)
|
2002-04-25 |
2003-12-18 |
Crucell Holland B.V. |
Means and methods for the production of adenovirus vectors
|
|
US6710173B1
(en)
|
1999-06-25 |
2004-03-23 |
Progenics Pharmaceuticals, Inc. |
Stabilized viral envelope proteins and uses thereof
|
|
EP1214333A4
(en)
|
1999-09-17 |
2005-01-19 |
Dana Farber Cancer Inst Inc |
SOLUBLE STABILIZED GLYCOPROTEIN TRIMERS
|
|
UA76731C2
(uk)
|
2000-11-23 |
2006-09-15 |
Баваріан Нордік А/С |
Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
|
|
EP2345665A3
(en)
|
2001-12-04 |
2012-02-15 |
Bavarian Nordic A/S |
Flavivirus NS1 subunit vaccine
|
|
AU2003291402A1
(en)
|
2002-11-07 |
2004-06-03 |
Beth Israel Deaconess Medical Center |
MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
|
|
JP2006509039A
(ja)
|
2002-12-03 |
2006-03-16 |
ユニバーシティ オブ マサチューセッツ |
多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
|
|
EP2363143A3
(en)
|
2003-03-28 |
2012-02-15 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
MVA expressing modified hiv envelope, gag, and pol genes
|
|
WO2005027840A2
(en)
|
2003-09-15 |
2005-03-31 |
Chiron Corporation |
Combination approaches for generating immune responses
|
|
US20070298051A1
(en)
|
2003-11-19 |
2007-12-27 |
Beth Israel Deaconess Medical Center |
Adjuvants Of Immune Response
|
|
EP1766097A4
(en)
|
2004-06-15 |
2008-03-19 |
Progenics Pharm Inc |
HIV-1 NEUTRALIZING ANTIBODIES INDUCED BY A TRIMER HIV-1 HYLLGLYCOPROTEIN COMPLEX
|
|
AU2005274948B2
(en)
|
2004-07-16 |
2011-09-22 |
Genvec, Inc. |
Vaccines against aids comprising CMV/R-nucleic acid constructs
|
|
AP2351A
(en)
|
2004-10-13 |
2012-01-25 |
Crucell Holland Bv |
Improved adenoviral vectors and uses thereof.
|
|
CA2656741A1
(en)
|
2005-07-06 |
2007-01-11 |
University Of Maryland Biotechnology Institute |
Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
|
|
CN101969996A
(zh)
|
2005-08-23 |
2011-02-09 |
加利福尼亚大学董事会 |
多价疫苗
|
|
WO2007104792A2
(en)
|
2006-03-16 |
2007-09-20 |
Crucell Holland B.V. |
Recombinant adenoviruses based on serotype 26 and 48, and use thereof
|
|
EP2040747A4
(en)
|
2006-06-19 |
2010-08-25 |
Progenics Pharm Inc |
SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE
|
|
US7939083B2
(en)
|
2006-10-23 |
2011-05-10 |
Progenics Pharmaceuticals Inc. |
Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
|
|
US20080279879A1
(en)
|
2006-11-17 |
2008-11-13 |
New York University |
INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
|
|
PL2137210T3
(pl)
|
2007-03-02 |
2017-06-30 |
Glaxosmithkline Biologicals Sa |
Nowy sposób i kompozycje
|
|
SMT202000101T1
(it)
|
2008-10-10 |
2020-03-13 |
Childrens Medical Center |
Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
|
|
NZ602504A
(en)
|
2008-11-18 |
2014-01-31 |
Beth Israel Hospital |
Antiviral vaccines with improved cellular immunogenicity
|
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
|
WO2011082087A2
(en)
|
2010-01-04 |
2011-07-07 |
Kj Biosciences, Llc |
Dps fusion proteins for use in vaccines and diagnostics
|
|
CA2786333C
(en)
|
2010-01-28 |
2018-03-20 |
Bavarian Nordic A/S |
Vaccinia virus mutants containing the major genomic deletions of mva
|
|
PT3556396T
(pt)
|
2010-08-31 |
2022-07-04 |
Scripps Research Inst |
Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
|
|
WO2013036791A2
(en)
|
2011-09-09 |
2013-03-14 |
Beth Israel Deaconess Medical Center, Inc. |
Modified adenoviral vectors and methods of treatment using same
|
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
|
WO2013055908A1
(en)
|
2011-10-12 |
2013-04-18 |
The Scripps Research Institute |
An hiv-1 gp120 mini v3 loop and uses thereof
|
|
US9683268B2
(en)
|
2012-09-19 |
2017-06-20 |
Beth Israel Deaconess |
Viruses associated with immunodeficiency and enteropathy and methods using same
|
|
US10106781B2
(en)
|
2012-11-16 |
2018-10-23 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and use thereof
|
|
SG10201705880QA
(en)
|
2013-01-07 |
2017-08-30 |
Beth Israel Deaconess Medical Ct Inc |
Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
|
|
US10248758B2
(en)
|
2013-02-07 |
2019-04-02 |
University Of Washington Through Its Center For Commercialization |
Self-assembling protein nanostructures
|
|
WO2015048770A2
(en)
|
2013-09-30 |
2015-04-02 |
Beth Israel Deaconess Medical Center, Inc. |
Antibody therapies for human immunodeficiency virus (hiv)
|
|
CA2941116A1
(en)
*
|
2014-02-28 |
2015-09-03 |
Janssen Vaccines & Prevention B.V. |
Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
|
|
WO2016037154A1
(en)
|
2014-09-04 |
2016-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant hiv-1 envelope proteins and their use
|
|
CN106999571B
(zh)
|
2014-09-26 |
2020-10-02 |
贝斯以色列护理医疗中心有限公司 |
诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
|
|
US9630994B2
(en)
|
2014-11-03 |
2017-04-25 |
University Of Washington |
Polypeptides for use in self-assembling protein nanostructures
|
|
DK3584252T3
(da)
|
2015-12-15 |
2021-11-15 |
Janssen Vaccines & Prevention Bv |
Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf
|
|
MA45381A
(fr)
|
2016-06-16 |
2021-04-21 |
Janssen Vaccines & Prevention Bv |
Formulation de vaccin contre le vih
|
|
JP2019526580A
(ja)
|
2016-09-02 |
2019-09-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
|
|
PT3512543T
(pt)
|
2016-09-15 |
2020-10-13 |
Janssen Vaccines & Prevention Bv |
Trímero que estabiliza mutações das proteínas do envelope do hiv
|